Trial designs used to study neuroprotective therapy in Parkinson's disease
Identifieur interne : 000947 ( Istex/Corpus ); précédent : 000946; suivant : 000948Trial designs used to study neuroprotective therapy in Parkinson's disease
Auteurs : Anthony E. Lang ; Eldad Melamed ; Werner Poewe ; Olivier RascolSource :
- Movement Disorders [ 0885-3185 ] ; 2013-01.
Abstract
There have been numerous trials conducted to evaluate putative disease‐modifying or neuroprotective treatments in Parkinson's disease. These trials have used several different study designs and outcome measures. Each of these has its own strengths and weaknesses. Confounding all studies is the potential symptomatic benefit that the treatment might have on the features of Parkinson's disease. In addition, patient‐related factors such as age of onset and the nature of the dominant symptoms may have important impacts that are often not addressed. Here we provide an overview of the various trial designs that have been used and emphasize the challenges faced in attempting to study neuroprotection in Parkinson's disease and the advances needed before this goal can be successfully achieved. © 2013 Movement Disorder Society
Url:
DOI: 10.1002/mds.24997
Links to Exploration step
ISTEX:1F8441423F9E5A20B3681C5AA731F29E6D85371FLe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Trial designs used to study neuroprotective therapy in Parkinson's disease</title><author><name sortKey="Lang, Anthony E" sort="Lang, Anthony E" uniqKey="Lang A" first="Anthony E." last="Lang">Anthony E. Lang</name><affiliation><mods:affiliation>Morton and Gloria Shulman Movement Disorders Clinic and the Edmond J Safra Program in Parkinson's Disease, Toronto Western Hospital, Ontario, Toronto, Canada</mods:affiliation></affiliation><affiliation><mods:affiliation>E-mail: lang@uhnres.utoronto.ca</mods:affiliation></affiliation></author><author><name sortKey="Melamed, Eldad" sort="Melamed, Eldad" uniqKey="Melamed E" first="Eldad" last="Melamed">Eldad Melamed</name><affiliation><mods:affiliation>The Norma and Alan Aufzien Chair for Resarch of Parkinson's Disease, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel</mods:affiliation></affiliation></author><author><name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name><affiliation><mods:affiliation>Department of Neurology, Innsbruck Medical University, Innsbruck, Austria</mods:affiliation></affiliation></author><author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name><affiliation><mods:affiliation>Clinical Investigation Center and Department of Clinical Pharmacology and Neurosciences, CIC9302 INSERM and UMR825, Toulouse University Hospital, University of Toulouse‐3, Toulouse, France</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:1F8441423F9E5A20B3681C5AA731F29E6D85371F</idno><date when="2013" year="2013">2013</date><idno type="doi">10.1002/mds.24997</idno><idno type="url">https://api-v5.istex.fr/document/1F8441423F9E5A20B3681C5AA731F29E6D85371F/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000947</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000947</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Trial designs used to study neuroprotective therapy in Parkinson's disease</title><author><name sortKey="Lang, Anthony E" sort="Lang, Anthony E" uniqKey="Lang A" first="Anthony E." last="Lang">Anthony E. Lang</name><affiliation><mods:affiliation>Morton and Gloria Shulman Movement Disorders Clinic and the Edmond J Safra Program in Parkinson's Disease, Toronto Western Hospital, Ontario, Toronto, Canada</mods:affiliation></affiliation><affiliation><mods:affiliation>E-mail: lang@uhnres.utoronto.ca</mods:affiliation></affiliation></author><author><name sortKey="Melamed, Eldad" sort="Melamed, Eldad" uniqKey="Melamed E" first="Eldad" last="Melamed">Eldad Melamed</name><affiliation><mods:affiliation>The Norma and Alan Aufzien Chair for Resarch of Parkinson's Disease, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel</mods:affiliation></affiliation></author><author><name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name><affiliation><mods:affiliation>Department of Neurology, Innsbruck Medical University, Innsbruck, Austria</mods:affiliation></affiliation></author><author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name><affiliation><mods:affiliation>Clinical Investigation Center and Department of Clinical Pharmacology and Neurosciences, CIC9302 INSERM and UMR825, Toulouse University Hospital, University of Toulouse‐3, Toulouse, France</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov Disord</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Blackwell Publishing Ltd</publisher><date type="published" when="2013-01">2013-01</date><biblScope unit="volume">28</biblScope><biblScope unit="issue">1</biblScope><biblScope unit="page" from="86">86</biblScope><biblScope unit="page" to="95">95</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">1F8441423F9E5A20B3681C5AA731F29E6D85371F</idno><idno type="DOI">10.1002/mds.24997</idno><idno type="ArticleID">MDS24997</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract">There have been numerous trials conducted to evaluate putative disease‐modifying or neuroprotective treatments in Parkinson's disease. These trials have used several different study designs and outcome measures. Each of these has its own strengths and weaknesses. Confounding all studies is the potential symptomatic benefit that the treatment might have on the features of Parkinson's disease. In addition, patient‐related factors such as age of onset and the nature of the dominant symptoms may have important impacts that are often not addressed. Here we provide an overview of the various trial designs that have been used and emphasize the challenges faced in attempting to study neuroprotection in Parkinson's disease and the advances needed before this goal can be successfully achieved. © 2013 Movement Disorder Society</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Anthony E. Lang MD</name><affiliations><json:string>Morton and Gloria Shulman Movement Disorders Clinic and the Edmond J Safra Program in Parkinson's Disease, Toronto Western Hospital, Ontario, Toronto, Canada</json:string><json:string>E-mail: lang@uhnres.utoronto.ca</json:string></affiliations></json:item><json:item><name>Eldad Melamed MD</name><affiliations><json:string>The Norma and Alan Aufzien Chair for Resarch of Parkinson's Disease, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel</json:string></affiliations></json:item><json:item><name>Werner Poewe MD</name><affiliations><json:string>Department of Neurology, Innsbruck Medical University, Innsbruck, Austria</json:string></affiliations></json:item><json:item><name>Olivier Rascol MD</name><affiliations><json:string>Clinical Investigation Center and Department of Clinical Pharmacology and Neurosciences, CIC9302 INSERM and UMR825, Toulouse University Hospital, University of Toulouse‐3, Toulouse, France</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>Parkinson's disease</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>neuroprotection</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>disease modification</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>trial designs</value></json:item></subject><articleId><json:string>MDS24997</json:string></articleId><language><json:string>eng</json:string></language><originalGenre><json:string>reviewArticle</json:string></originalGenre><abstract>There have been numerous trials conducted to evaluate putative disease‐modifying or neuroprotective treatments in Parkinson's disease. These trials have used several different study designs and outcome measures. Each of these has its own strengths and weaknesses. Confounding all studies is the potential symptomatic benefit that the treatment might have on the features of Parkinson's disease. In addition, patient‐related factors such as age of onset and the nature of the dominant symptoms may have important impacts that are often not addressed. Here we provide an overview of the various trial designs that have been used and emphasize the challenges faced in attempting to study neuroprotection in Parkinson's disease and the advances needed before this goal can be successfully achieved. © 2013 Movement Disorder Society</abstract><qualityIndicators><score>6.476</score><pdfVersion>1.3</pdfVersion><pdfPageSize>612 x 809.972 pts</pdfPageSize><refBibsNative>true</refBibsNative><abstractCharCount>827</abstractCharCount><pdfWordCount>6457</pdfWordCount><pdfCharCount>42424</pdfCharCount><pdfPageCount>10</pdfPageCount><abstractWordCount>123</abstractWordCount></qualityIndicators><title>Trial designs used to study neuroprotective therapy in Parkinson's disease</title><genre><json:string>review-article</json:string></genre><host><title>Movement Disorders</title><language><json:string>unknown</json:string></language><doi><json:string>10.1002/(ISSN)1531-8257</json:string></doi><issn><json:string>0885-3185</json:string></issn><eissn><json:string>1531-8257</json:string></eissn><publisherId><json:string>MDS</json:string></publisherId><volume>28</volume><issue>1</issue><pages><first>86</first><last>95</last><total>10</total></pages><genre><json:string>journal</json:string></genre><subject><json:item><value>Review</value></json:item></subject></host><categories><wos><json:string>science</json:string><json:string>clinical neurology</json:string></wos><scienceMetrix><json:string>health sciences</json:string><json:string>clinical medicine</json:string><json:string>neurology & neurosurgery</json:string></scienceMetrix></categories><publicationDate>2013</publicationDate><copyrightDate>2013</copyrightDate><doi><json:string>10.1002/mds.24997</json:string></doi><id>1F8441423F9E5A20B3681C5AA731F29E6D85371F</id><fulltext><json:item><extension>pdf</extension><original>true</original><mimetype>application/pdf</mimetype><uri>https://api-v5.istex.fr/document/1F8441423F9E5A20B3681C5AA731F29E6D85371F/fulltext/pdf</uri></json:item><json:item><extension>zip</extension><original>false</original><mimetype>application/zip</mimetype><uri>https://api-v5.istex.fr/document/1F8441423F9E5A20B3681C5AA731F29E6D85371F/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api-v5.istex.fr/document/1F8441423F9E5A20B3681C5AA731F29E6D85371F/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Trial designs used to study neuroprotective therapy in Parkinson's disease</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Blackwell Publishing Ltd</publisher><availability><p>Copyright © 2013 Movement Disorder SocietyCopyright © 2013 Movement Disorders Society</p></availability><date>2013-02-06</date></publicationStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Trial designs used to study neuroprotective therapy in Parkinson's disease</title><author xml:id="author-1"><persName><forename type="first">Anthony E.</forename><surname>Lang</surname></persName><roleName type="degree">MD</roleName><email>lang@uhnres.utoronto.ca</email><affiliation>Morton and Gloria Shulman Movement Disorders Clinic and the Edmond J Safra Program in Parkinson's Disease, Toronto Western Hospital, Ontario, Toronto, Canada</affiliation></author><author xml:id="author-2"><persName><forename type="first">Eldad</forename><surname>Melamed</surname></persName><roleName type="degree">MD</roleName><affiliation>The Norma and Alan Aufzien Chair for Resarch of Parkinson's Disease, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel</affiliation></author><author xml:id="author-3"><persName><forename type="first">Werner</forename><surname>Poewe</surname></persName><roleName type="degree">MD</roleName><affiliation>Department of Neurology, Innsbruck Medical University, Innsbruck, Austria</affiliation></author><author xml:id="author-4"><persName><forename type="first">Olivier</forename><surname>Rascol</surname></persName><roleName type="degree">MD</roleName><affiliation>Clinical Investigation Center and Department of Clinical Pharmacology and Neurosciences, CIC9302 INSERM and UMR825, Toulouse University Hospital, University of Toulouse‐3, Toulouse, France</affiliation></author></analytic><monogr><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov Disord</title><idno type="pISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><idno type="DOI">10.1002/(ISSN)1531-8257</idno><imprint><publisher>Blackwell Publishing Ltd</publisher><date type="published" when="2013-01"></date><biblScope unit="volume">28</biblScope><biblScope unit="issue">1</biblScope><biblScope unit="page" from="86">86</biblScope><biblScope unit="page" to="95">95</biblScope></imprint></monogr><idno type="istex">1F8441423F9E5A20B3681C5AA731F29E6D85371F</idno><idno type="DOI">10.1002/mds.24997</idno><idno type="ArticleID">MDS24997</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2013-02-06</date></creation><langUsage><language ident="en">en</language></langUsage><abstract><p>There have been numerous trials conducted to evaluate putative disease‐modifying or neuroprotective treatments in Parkinson's disease. These trials have used several different study designs and outcome measures. Each of these has its own strengths and weaknesses. Confounding all studies is the potential symptomatic benefit that the treatment might have on the features of Parkinson's disease. In addition, patient‐related factors such as age of onset and the nature of the dominant symptoms may have important impacts that are often not addressed. Here we provide an overview of the various trial designs that have been used and emphasize the challenges faced in attempting to study neuroprotection in Parkinson's disease and the advances needed before this goal can be successfully achieved. © 2013 Movement Disorder Society</p></abstract><textClass><keywords scheme="keyword"><list><head>keywords</head><item><term>Parkinson's disease</term></item><item><term>neuroprotection</term></item><item><term>disease modification</term></item><item><term>trial designs</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>article-category</head><item><term>Review</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2011-12-23">Received</change><change when="2012-03-14">Registration</change><change when="2013-02-06">Created</change><change when="2013-01">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><extension>txt</extension><original>false</original><mimetype>text/plain</mimetype><uri>https://api-v5.istex.fr/document/1F8441423F9E5A20B3681C5AA731F29E6D85371F/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en" xml:id="mds24997"><header><publicationMeta level="product"><doi origin="wiley" registered="yes">10.1002/(ISSN)1531-8257</doi><issn type="print">0885-3185</issn><issn type="electronic">1531-8257</issn><idGroup><id type="product" value="MDS"></id></idGroup><titleGroup><title type="main" sort="MOVEMENT DISORDERS">Movement Disorders</title><title type="short">Mov Disord</title></titleGroup></publicationMeta><publicationMeta level="part" position="10"><doi>10.1002/mds.v28.1</doi><titleGroup><title type="specialIssueTitle">The Vatican Conference on Neuroprotection in Parkinson's Disease</title></titleGroup><copyright ownership="publisher">Copyright © 2013 Movement Disorder Society</copyright><numberingGroup><numbering type="journalVolume" number="28">28</numbering><numbering type="journalIssue">1</numbering></numberingGroup><coverDate startDate="2013-01">January 2013</coverDate></publicationMeta><publicationMeta level="unit" position="110" type="reviewArticle" status="forIssue"><doi>10.1002/mds.24997</doi><idGroup><id type="unit" value="MDS24997"></id></idGroup><countGroup><count type="pageTotal" number="10"></count></countGroup><titleGroup><title type="articleCategory">Review</title><title type="tocHeading1">Reviews</title></titleGroup><copyright ownership="publisher">Copyright © 2013 Movement Disorders Society</copyright><eventGroup><event type="manuscriptReceived" date="2011-12-23"></event><event type="manuscriptRevised" date="2012-01-31"></event><event type="manuscriptAccepted" date="2012-03-14"></event><event type="xmlCreated" agent="Cenveo Publisher Services" date="2013-02-06"></event><event type="publishedOnlineEarlyUnpaginated" date="2012-08-23"></event><event type="firstOnline" date="2012-08-23"></event><event type="publishedOnlineFinalForm" date="2013-02-06"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-02"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.6.4 mode:FullText" date="2015-10-03"></event></eventGroup><numberingGroup><numbering type="pageFirst">86</numbering><numbering type="pageLast">95</numbering></numberingGroup><correspondenceTo><b>Correspondence to:</b> Dr. Anthony E. Lang, Movement Disorders Center, Toronto Western Hospital, 399 Bathurst St, 7 McL, Toronto, ON, Canada M5T 2S8; <email>lang@uhnres.utoronto.ca</email></correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:MDS.MDS24997.pdf"></link></linkGroup></publicationMeta><contentMeta><titleGroup><title type="main">Trial designs used to study neuroprotective therapy in Parkinson's disease</title><title type="short">PD Neuroprotective Therapy: Trial Designs</title></titleGroup><creators><creator affiliationRef="#mds24997-aff-0001" corresponding="yes" creatorRole="author" xml:id="mds24997-cr-0001"><personName><givenNames>Anthony E.</givenNames><familyName>Lang</familyName><degrees>MD</degrees></personName></creator><creator affiliationRef="#mds24997-aff-0002" creatorRole="author" xml:id="mds24997-cr-0002"><personName><givenNames>Eldad</givenNames><familyName>Melamed</familyName><degrees>MD</degrees></personName></creator><creator affiliationRef="#mds24997-aff-0003" creatorRole="author" xml:id="mds24997-cr-0003"><personName><givenNames>Werner</givenNames><familyName>Poewe</familyName><degrees>MD</degrees></personName></creator><creator affiliationRef="#mds24997-aff-0004" creatorRole="author" xml:id="mds24997-cr-0004"><personName><givenNames>Olivier</givenNames><familyName>Rascol</familyName><degrees>MD</degrees></personName></creator></creators><affiliationGroup><affiliation type="organization" xml:id="mds24997-aff-0001" countryCode="CA"><orgDiv>Morton and Gloria Shulman Movement Disorders Clinic and the Edmond J Safra Program in Parkinson's Disease</orgDiv><orgName>Toronto Western Hospital</orgName><address><city>Toronto</city><countryPart>Ontario</countryPart><country>Canada</country></address></affiliation><affiliation type="organization" xml:id="mds24997-aff-0002" countryCode="IL"><orgDiv>The Norma and Alan Aufzien Chair for Resarch of Parkinson's Disease</orgDiv><orgName>Tel Aviv University</orgName><orgDiv>Sackler School of Medicine</orgDiv><address><city>Tel Aviv</city><country>Israel</country></address></affiliation><affiliation type="organization" xml:id="mds24997-aff-0003" countryCode="AU"><orgDiv>Department of Neurology</orgDiv><orgName>Innsbruck Medical University</orgName><address><city>Innsbruck</city><country>Austria</country></address></affiliation><affiliation type="organization" xml:id="mds24997-aff-0004" countryCode="FR"><orgDiv>Clinical Investigation Center and Department of Clinical Pharmacology and Neurosciences</orgDiv><orgDiv>CIC9302 INSERM and UMR825</orgDiv><orgDiv>Toulouse University Hospital</orgDiv><orgName>University of Toulouse‐3</orgName><address><city>Toulouse</city><country>France</country></address></affiliation></affiliationGroup><keywordGroup type="author"><keyword xml:id="mds24997-kwd-0001">Parkinson's disease</keyword><keyword xml:id="mds24997-kwd-0002">neuroprotection</keyword><keyword xml:id="mds24997-kwd-0003">disease modification</keyword><keyword xml:id="mds24997-kwd-0004">trial designs</keyword></keywordGroup><abstractGroup><abstract type="main"><p>There have been numerous trials conducted to evaluate putative disease‐modifying or neuroprotective treatments in Parkinson's disease. These trials have used several different study designs and outcome measures. Each of these has its own strengths and weaknesses. Confounding all studies is the potential symptomatic benefit that the treatment might have on the features of Parkinson's disease. In addition, patient‐related factors such as age of onset and the nature of the dominant symptoms may have important impacts that are often not addressed. Here we provide an overview of the various trial designs that have been used and emphasize the challenges faced in attempting to study neuroprotection in Parkinson's disease and the advances needed before this goal can be successfully achieved. © 2013 Movement Disorder Society</p></abstract></abstractGroup></contentMeta><noteGroup><note xml:id="mds24997-note-0001"><p><b>Relevant conflicts of interest/financial disclosures:</b> Nothing to report.</p></note><note xml:id="mds24997-note-0002"><p>Full financial disclosures and author roles may be found in the online version of this article.</p></note><note xml:id="mds24997-note-0003"><p><b>Funding:</b> This work was partially funded by a Center of Excellence grant to Anthony E. Lang from the National Parkinson Foundation.</p></note></noteGroup></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Trial designs used to study neuroprotective therapy in Parkinson's disease</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>PD Neuroprotective Therapy: Trial Designs</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Trial designs used to study neuroprotective therapy in Parkinson's disease</title></titleInfo><name type="personal"><namePart type="given">Anthony E.</namePart><namePart type="family">Lang</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Morton and Gloria Shulman Movement Disorders Clinic and the Edmond J Safra Program in Parkinson's Disease, Toronto Western Hospital, Ontario, Toronto, Canada</affiliation><affiliation>E-mail: lang@uhnres.utoronto.ca</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Eldad</namePart><namePart type="family">Melamed</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>The Norma and Alan Aufzien Chair for Resarch of Parkinson's Disease, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Werner</namePart><namePart type="family">Poewe</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurology, Innsbruck Medical University, Innsbruck, Austria</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Olivier</namePart><namePart type="family">Rascol</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Clinical Investigation Center and Department of Clinical Pharmacology and Neurosciences, CIC9302 INSERM and UMR825, Toulouse University Hospital, University of Toulouse‐3, Toulouse, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="review-article" displayLabel="reviewArticle"></genre><originInfo><publisher>Blackwell Publishing Ltd</publisher><dateIssued encoding="w3cdtf">2013-01</dateIssued><dateCreated encoding="w3cdtf">2013-02-06</dateCreated><dateCaptured encoding="w3cdtf">2011-12-23</dateCaptured><dateValid encoding="w3cdtf">2012-03-14</dateValid><copyrightDate encoding="w3cdtf">2013</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType></physicalDescription><abstract>There have been numerous trials conducted to evaluate putative disease‐modifying or neuroprotective treatments in Parkinson's disease. These trials have used several different study designs and outcome measures. Each of these has its own strengths and weaknesses. Confounding all studies is the potential symptomatic benefit that the treatment might have on the features of Parkinson's disease. In addition, patient‐related factors such as age of onset and the nature of the dominant symptoms may have important impacts that are often not addressed. Here we provide an overview of the various trial designs that have been used and emphasize the challenges faced in attempting to study neuroprotection in Parkinson's disease and the advances needed before this goal can be successfully achieved. © 2013 Movement Disorder Society</abstract><subject><genre>keywords</genre><topic>Parkinson's disease</topic><topic>neuroprotection</topic><topic>disease modification</topic><topic>trial designs</topic></subject><relatedItem type="host"><titleInfo><title>Movement Disorders</title></titleInfo><titleInfo type="abbreviated"><title>Mov Disord</title></titleInfo><genre type="journal">journal</genre><subject><genre>article-category</genre><topic>Review</topic></subject><identifier type="ISSN">0885-3185</identifier><identifier type="eISSN">1531-8257</identifier><identifier type="DOI">10.1002/(ISSN)1531-8257</identifier><identifier type="PublisherID">MDS</identifier><part><date>2013</date><detail type="title"><title>The Vatican Conference on Neuroprotection in Parkinson's Disease</title></detail><detail type="volume"><caption>vol.</caption><number>28</number></detail><detail type="issue"><caption>no.</caption><number>1</number></detail><extent unit="pages"><start>86</start><end>95</end><total>10</total></extent></part></relatedItem><identifier type="istex">1F8441423F9E5A20B3681C5AA731F29E6D85371F</identifier><identifier type="DOI">10.1002/mds.24997</identifier><identifier type="ArticleID">MDS24997</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 2013 Movement Disorder SocietyCopyright © 2013 Movement Disorders Society</accessCondition><recordInfo><recordContentSource>WILEY</recordContentSource></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000947 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 000947 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:1F8441423F9E5A20B3681C5AA731F29E6D85371F
|texte= Trial designs used to study neuroprotective therapy in Parkinson's disease
}}
| This area was generated with Dilib version V0.6.29. |  |